ArticleJournal of the Egyptian National Cancer Institute2026
Positive rates of endometrial and cervical cytology in ovarian cancer patients with BRCA1/2 germline pathogenic variants.
Article in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal approach for early-stage ovarian cancer detection remains unclear, particularly in patients with hereditary breast and ovarian cancer (HBOC). As ovarian cancer in HBOC is often thought to originate from the fallopian tube fimbriae, endometrial cytology may play a role in detecting early-stage disease. This retrospective study aimed to assess the positive rate of endometrial cytology and compare to cervical cytology in ovarian cancer patients with patients with BRCA1/2 germline pathogenic variants (gPV).
methodsPatients with genetically confirmed BRCA1/2 gPV diagnosed with ovarian, fallopian tube, or primary peritoneal cancer from May 1998 to April 2024 at our institution were included. Those who underwent endometrial and cervical cytology prior to initial treatment were eligible for this analysis. The positive rates for each cytology type were evaluated.
resultsA total of 154 patients with BRCA1/2 gPV were enrolled, 118 underwent both endometrial and cervical cytology. The positive rate for endometrial cytology was significantly higher than that for cervical cytology (36.4% vs. 15.3%; p < 0.001). Additionally, a correlation was observed between the positive rate of endometrial cytology and cancer stage (Stage I 16.6%, Stage II 25%, Stage III 41.5%, Stage IV 58.6%; r = 0.9895).
conclusionIn this retrospective study, the positive rate of endometrial cytology surpassed that of cervical cytology. Endometrial cytology may play a role as a potential surveillance tool for women with BRCA1/2 gPV, even at early stages of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.